GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Alexion Pharmaceuticals, Inc. (ALXN) [hlAlert]

Rating:
Buy ALXN
up 93.43 %

Alexion Pharmaceuticals, Inc. (ALXN) rated Buy with price target $200 by Canaccord Genuity

Posted on: Friday,  Jan 31, 2014  11:25 AM ET by Canaccord Genuity

Canaccord Genuity rated Buy Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) on 01/31/2014. Previously Canaccord Genuity rated Buy Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) on
03/26/2012., when the stock price was $92.96. Since then, Alexion Pharmaceuticals, Inc. has gained 93.44% as of 12/11/2015's recent price of $179.82.
If you would have followed the previous Canaccord Genuity's recommendation on ALXN, you would have gained 93.43% of your investment in 1355 days.

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.

Canaccord Genuity’s global team of over 100 research professionals are inquisitive, experienced and committed to generating actionable investment ideas. We analyze over 725 companies in a broad range of market sectors, identifying value and defining risk for our clients.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/31/2014 11:25 AM Buy
None
159.38 200.00
as of 10/17/2014
1 Week down  -1.81 %
1 Month up  1.99 %
3 Months up  6.24 %
1 YTD up  23.98 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/24/2012 8:25 AM Buy
None
113.89 132.00
4/25/2012 9:25 AM Buy
None
89.32 100.00
3/26/2012 9:25 AM Buy
None
92.96 95.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy